Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1993-03-19
1995-11-28
Robinson, Douglas W.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 72, 536 73, C07J 1708, A61K 3170
Patent
active
054709610
ABSTRACT:
Disclosed are (1) a structurally novel 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof, which has an excellent gastrointestinal function promoting effect and is low in toxicity; (2) a process for preparing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof, which comprises reacting a 6,9-hemiacetal-erythromycin derivative or a salt thereof with an organism-derived oxidase; and (3) a gastrointestinal function promoting agent containing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof.
REFERENCES:
patent: 4672056 (1987-06-01), Fernandes et al.
patent: 4920102 (1990-04-01), Gidda et al.
patent: 4975370 (1990-12-01), Sasaki et al.
patent: 5008249 (1991-04-01), Omura et al.
Ferrero et al. Drug Metab. Dispos., vol. 18(4), pp. 441-446, (1990).
Sasaki et al. The Journal of Antibiotics, vol. 41(7), pp. 908-915, (1988).
Tsuzuki, Kazuo, Chem. Pharm. Bull 37(10) 2687-2700 (1989).
Omura, Satoshi, et al., Journal of Medicinal Chemistry, vol. 30:11 1941-1943 (1987).
Funabashi Yasunori
Harada Setsuo
Inatomi Nobuhiro
Tanayama Shigeharu
Tanida Seiichi
Conlin David G.
Eisenstein Ronald I.
Kitasato Kenkyushio
Lee Howard C.
Robinson Douglas W.
LandOfFree
14 and/or 15-hydroxy 6,9 hemiacetal erythromycin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 14 and/or 15-hydroxy 6,9 hemiacetal erythromycin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 14 and/or 15-hydroxy 6,9 hemiacetal erythromycin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2014602